UXIN
UXIN: Dai Kun discloses a purchase
Dai Kun reported Purchase in Uxin Ltd: 11836 units of American depositary shares, dated 2026-10-08. The full Form 4 contains 1 transaction entry.
LoadingLoadingLoadingUXIN
Dai Kun reported Purchase in Uxin Ltd: 11836 units of American depositary shares, dated 2026-10-08. The full Form 4 contains 1 transaction entry.
AGMB
Epstein David R reported Purchase in AgomAb Therapeutics NV: 5000 units of Common shares, dated 2026-10-08. The full Form 4 contains 1 transaction entry.
CHKP
SHWED GIL reported Gift in CHECK POINT SOFTWARE TECHNOLOGIES LTD: 4000 units of Ordinary Shares, NIS 0.01 Per Share, dated 2026-08-05. The full Form 4 contains 2 transaction entries.
TRXB
Ross Michael Jay reported Grant or award in TRex Bio, Inc.: 17500 units of Stock Option (Right to Buy) (derivative), dated 2026-10-08. The full Form 4 contains 1 transaction entry.
RTSN
Olds Donald reported Grant or award in Retension Pharmaceuticals, Inc.: 5636 units of Stock Option (right to buy) (derivative), dated 2026-10-08. The full Form 4 contains 1 transaction entry.
TRXB
MARCUS JOEL S reported Grant or award in TRex Bio, Inc.: 17500 units of Stock Option (Right to Buy) (derivative), dated 2026-10-08. The full Form 4 contains 1 transaction entry.
NONE
Rynders Perry M. reported 500 shares of Common Stock in Lodging Fund REIT III, Inc. as grants or awards dated 2026-09-30. The Form 4 was disclosed on Oct 8, 2026. These were stock awards, not open-market purchases.
NONE
Leighton Jeffrey T. reported 500 shares of Common Stock in Lodging Fund REIT III, Inc. as grants or awards dated 2026-09-30. The Form 4 was disclosed on Oct 8, 2026. These were stock awards, not open-market purchases.
TXTM
Jamaloodeen Ahmed reported Grant or award in ProText Mobility, Inc.: 66667 units of Series D Preferred Stock, dated 2022-06-03. The full Form 4 contains 9 transaction entries.
TRXB
Hirth Peter reported Grant or award in TRex Bio, Inc.: 17500 units of Stock Option (Right to Buy) (derivative), dated 2026-10-08. The full Form 4 contains 1 transaction entry.
TRXB
Gilmore Julie Ann reported Grant or award in TRex Bio, Inc.: 17500 units of Stock Option (Right to Buy) (derivative), dated 2026-10-08. The full Form 4 contains 1 transaction entry.
TRXB
Gallagher Carol Giltner reported Grant or award in TRex Bio, Inc.: 17500 units of Stock Option (Right to Buy) (derivative), dated 2026-10-08. The full Form 4 contains 1 transaction entry.
NONE
Hall Bjorn reported Purchase in Fundrise Income Real Estate Fund, LLC: 98.8142 units of Common Shares, dated 2026-10-07. The full Form 4 contains 1 transaction entry.
NONE
Ungerecht Joshua reported Grant or award in ExchangeRight Income Fund: 16347.2675 units of NLP 53 Common Units (derivative), dated 2026-10-06. The full Form 4 contains 2 transaction entries.
NONE
Thomas Warren reported Grant or award in ExchangeRight Income Fund: 16596.3702 units of NLP 53 Common Units (derivative), dated 2026-10-06. The full Form 4 contains 1 transaction entry.
TRXB
Coy Travis Alan reported Grant or award in TRex Bio, Inc.: 17500 units of Stock Option (Right to Buy) (derivative), dated 2026-10-08. The full Form 4 contains 1 transaction entry.
NONE
Booth Richard Whitaker reported Purchase in Fundrise Real Estate Interval Fund, LLC: 41.7362 units of Common Shares, dated 2026-10-07. The full Form 4 contains 1 transaction entry.
RTSN
BERGER FRANKLIN M reported Grant or award in Retension Pharmaceuticals, Inc.: 5636 units of Stock Option (right to buy) (derivative), dated 2026-10-08. The full Form 4 contains 1 transaction entry.
RTSN
BERENDT MICHAEL J reported Grant or award in Retension Pharmaceuticals, Inc.: 5636 units of Stock Option (right to buy) (derivative), dated 2026-10-08. The full Form 4 contains 1 transaction entry.
BLFS
Werner Sean reported Grant or award in BIOLIFE SOLUTIONS INC: 45838 units of Common Stock, dated 2026-10-06. The full Form 4 contains 4 transaction entries.
BLFS
Berard Todd reported Grant or award in BIOLIFE SOLUTIONS INC: 38198 units of Common Stock, dated 2026-10-06. The full Form 4 contains 4 transaction entries.
BLFS
Mathew Aby J. reported Grant or award in BIOLIFE SOLUTIONS INC: 45838 units of Common Stock, dated 2026-10-06. The full Form 4 contains 4 transaction entries.
BLFS
MOORE TIMOTHY L. reported Disposition to issuer in BIOLIFE SOLUTIONS INC: 44943 units of Common Stock, dated 2026-10-06. The full Form 4 contains 1 transaction entry.
BLFS
Hunt Anthony reported Disposition to issuer in BIOLIFE SOLUTIONS INC: 15046 units of Common Stock, dated 2026-10-06. The full Form 4 contains 1 transaction entry.
